Glucagon
- PDF / 169,797 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 46 Downloads / 175 Views
1 S
Diarrhoea and necrolytic migratory erythema following off label use: 2 case reports In a prospective observational study of 33 patients (recruited between 2007 and 2015), 2 children [ages and sexes not stated] were described, out of whom 1 child developed diarrhoea and another child developed necrolytic migratory erythema during off-label treatment with glucagon for congenital hyperinsulinism [time to reactions onsets not stated; not all outcomes stated]. The patients, who had congenital hyperinsulinism (CHI), started receiving off-label glucagon infusion in titrated dose, beginning at 5 µg/kg/hour and the dose was increased as needed. The dose of glucagon was drawn up and diluted with 0.9% sodium chloride solution to make up to 5mL in a 10mL syringe to give an initial rate of 0.2 mL/hour equating to 5 µg/kg/hour. Additionally, the patients received concomitant medications including glucose [dextrose], diazoxide and chlorothiazide. However, the patients developed adverse events secondary to glucagon infusion, out of whom 1 child developed diarrhoea, which was possibly related to glucagon infusion and another child developed necrolytic migratory erythema, who received glucagon infusion for 60 days (maximum dose of 20 µg/kg/hour). The rash disappeared once glucagon infusion was discontinued. Salomon-Estebanez M, et al. Efficacy of Dose-Titrated Glucagon Infusions in the Management of Congenital Hyperinsulinism: A Case Series. Frontiers in Endocrinology 11: 803506940 441, 3 Sep 2020. Available from: URL: http://doi.org/10.3389/fendo.2020.00441
0114-9954/20/1826-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 17 Oct 2020 No. 1826
Data Loading...
